

- **Name:** Jwa Hoon Kim
 - **Current Position & Affiliation:** Clinical Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, Korea University Anam Hospital
 - **Country:** Republic of Korea
-

• Educational Background:

- 2005. 3 – 2011. 2 M.D.
University of Kyung-hee, College of Medicine
Seoul, Korea
- 2014. 3 – 2016. 2 Master
University of Ulsan, College of Medicine
Seoul, Korea
- 2020. 3 – 2022. 2 Doctor of Philosophy
Master
University of Ulsan, College of Medicine
Seoul, Korea

• Professional Experience:

- 2011. 3 – 2012.2 Internship
Asan Medical Center,
University of Ulsan College of Medicine
Seoul, Korea
- 2012. 3 – 2016.2 Resident Physician, Department of Internal Medicine,
Asan Medical Center,
University of Ulsan College of Medicine
Seoul, Korea
- 2019. 5 – 2021. 2 Fellowship-training, Department of Oncology,
Asan Medical Center,
University of Ulsan College of Medicine
Seoul, Korea

• Professional Organizations:

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Cancer Association
- Member, Korean Society of Medical Oncology

• Main Scientific Publications:

- 1) **Predictive biomarkers for the efficacy of nivolumab $\geq 3^{\text{rd}}$ -line therapy in patients with advanced gastric cancer: A subset analysis of ATTRACTION-2 phase III trial.** *BMC cancer* 2022
- 2) **Histopathologic and molecular biomarkers of PD-1/PD-L1 inhibitor treatment response among patients with microsatellite instability-high colon cancer.** *Cancer Res Treat.* 2022.

- 3) **A Phase II Study of Avelumab Monotherapy in Patients With Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.** *Cancer Res Treat.* 2020.
- 4) **3'-Deoxy-3'-¹⁸F-Fluorothymidine and ¹⁸F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.** *Eur J Nucl Med Mol Imaging* 2019;46(8):1713-1722
- 5) **Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.** *Cancer Research and Treatment* 2021.
- 6) **Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer.** *Cancer Res Treat.* 2020.
- 7) **Clinical outcomes with Multikinase Inhibitors after Proression on First-line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.** *Liver Cancer.* 2021